ENTA
Enanta Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 21, 5:43 PM
    | Mon, Nov. 21, 5:43 PM | 9 Comments
  • Mon, Nov. 21, 4:16 PM
    • AbbVie (NYSE:ABBV) collaboration partner Enanta Pharmaceuticals (NASDAQ:ENTA) fiscal Q4 results ($M): Royalty Revenue: 12.8 (-10.9%).
    • Net Loss: (1.8) (-131.0%); Loss Per Share: (0.09) (-131.0%).
    • Consensus view was a loss/share of ($0.14) on revenues of $13.2M.
    • Shares are off a fraction after hours.
    | Mon, Nov. 21, 4:16 PM | 2 Comments
  • Mon, Nov. 21, 4:02 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ4 EPS of -$0.09 beats by $0.05.
    • Revenue of $12.84M (-11.0% Y/Y) misses by $0.39M.
    • Press Release
    | Mon, Nov. 21, 4:02 PM
  • Sun, Nov. 20, 5:35 PM
  • Mon, Aug. 8, 4:24 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ3 EPS of -$0.06 beats by $0.04.
    • Revenue of $14M (+20.7% Y/Y) beats by $0.95M.
    • Press Release
    | Mon, Aug. 8, 4:24 PM
  • Mon, Jun. 20, 10:06 AM
    • Enanta Pharmaceuticals (ENTA +2.5%commences the proof-of-concept portion of its ongoing Phase 1 study evaluating EDP-494, a pan-genotypic cyclophilin inhibitor, in patients with hepatitis C virus (HCV) genotypes 1 or 3 infection. The double-blind, randomized phase will assess the safety, pharmacokinetics and anti-viral activity of two different oral doses of EDP-494 in treatment-naive HCV patients, administered once daily for 14 days.
    • According to the company, there is increasing resistance to currently available direct-acting HCV antivirals (DAAs). EDP-494 avoids this problem via its unique mechanism of action, inhibiting a protein called cyclophilin which plays an essential role in HCV replication. EDP-494 is called a host-targeting antiviral which means that it targets the host proteins that are involved in the viral life cycle. Other HCV therapies are categorized as virus-targeting antivirals since they act directly on viral proteins. It says cyclophilin inhibitors may have the highest barrier to resistance of any class of HCV treatments.
    • After the Phase 1 is completed, Enanta intends to develop EDP-494, in combination with one or more DAAs, for treatment-resistant HCV infection.
    • HCV-related tickers: (GILD +1.6%)(JNJ +1.1%)(BMY +1%)(MRK +1%)(GSK +3.4%)(RGLS +0.7%)(ABBV +1.7%)
    | Mon, Jun. 20, 10:06 AM | 15 Comments
  • Mon, May 9, 4:10 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ2 EPS of -$0.09 misses by $0.19.
    • Revenue of $13M (-77.3% Y/Y) misses by $3.8M.
    | Mon, May 9, 4:10 PM
  • Fri, Apr. 15, 8:21 AM
    • Results from the ongoing Phase 2 MAGELLAN-1 study evaluating AbbVie's (NYSE:ABBV) pan-genotypic regimen of ABT-493 (300 mg) and ABT-530 (120 mg) with ribavirin (RBV) in patients with genotype 1 and genotypes 4-6 chronic hepatitis C virus (HCV) infection who failed previous therapy with direct-acting antivirals (DAAs) showed a 91% cure rate (SVR12) in the intent-to-treat population (n=20/22). In addition, 86% (n=19/22) of HCV-1 patients who received the regimen without ribavirin achieved SVR12. The data are being presented today at The International Liver Congress 2016 in Barcelona, Spain.
    • In a modified intent-to-treat analysis which excluded patients who did not achieve SVR for reasons other than virologic failure, 95% were cured (with or without ribavirin).
    • There were no discontinuations due to adverse events (AEs). Two patients experienced virologic failure, one from each arm (with/without ribavirin). The most common AEs reported were headache (30%), fatigue (27%) and nausea (20%).
    • ABT-493, an NS3/4A protease inhibitor, and  ABT-530, an NS5A inhibitor, are currently in Phase 3 development. ABT-493 was discovered under the company's collaboration with Enanta Pharmaceuticals (NASDAQ:ENTA).
    • Read now Purchase AbbVie: Doctor's Orders 
    | Fri, Apr. 15, 8:21 AM | 3 Comments
  • Tue, Feb. 9, 12:48 PM
    | Tue, Feb. 9, 12:48 PM
  • Mon, Feb. 8, 4:04 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ1 EPS of $1.36 beats by $0.23.
    • Revenue of $48.4M (-37.5% Y/Y) beats by $1.35M.
    | Mon, Feb. 8, 4:04 PM
  • Nov. 24, 2015, 7:28 AM
    • Enanta Pharmaceuticals (ENTA +1.5%) FQ4 results: Revenues: $14.4M (+453.8%); R&D Expense: $7M (+34.6%); SG&A: $3.7M (+32.1%); Operating Income: $3.7M (+169.8%); Net Income: $5.8M (+216.0%); EPS: $0.29 (+207.4%); Quick Assets: $145.2M (+59.9%).
    • FY2015 results: Revenues: $160.9M (+237.3%); R&D Expense: $23.2M (+24.1%); SG&A: $13.5M (+35.0%); Operating Income: $124.1M (+553.2%); Net Income: $79M (+129.7%); EPS: $4.09 (+127.2%); Quick Assets: $145.2M (+59.9%).
    • No guidance given.
    | Nov. 24, 2015, 7:28 AM | 2 Comments
  • Nov. 23, 2015, 4:05 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ4 EPS of $0.29 beats by $0.14.
    • Revenue of $14.42M (+446.2% Y/Y) misses by $2.02M.
    | Nov. 23, 2015, 4:05 PM
  • Nov. 22, 2015, 5:35 PM
  • Nov. 20, 2015, 9:31 AM
    • In a regulatory filing, Enanta Pharmaceuticals (NASDAQ:ENTA) discloses that it earned a $30M milestone payment from development partner AbbVie (NYSE:ABBV) triggered by the establishment of reimbursement for VIEKIRAX in Japan. The Japanese Ministry of Health, Labour and Welfare cleared it for sale in September.
    | Nov. 20, 2015, 9:31 AM | 6 Comments
  • Nov. 16, 2015, 10:07 AM
    • Data from two mid-stage clinical trials, SURVEYOR-I and SURVEYOR-II, show AbbVie's (ABBV +1.3%) investigational HCV regimen, ABT-493 and ABT-530, produced cure rates as high as 100% after 12 weeks of treatment. The results are being presented at The Liver Meeting in San Francisco.
    • Results from the two ongoing studies include genotypes 1, 2 and 3. Data from genotypes 4 - 6 will be presented at future meetings.
    • SURVEYOR-I is assessing ABT-493 and ABT-530, with and without ribavirin, in cirrhotic and non-cirrhotic adult HCV-1 patients and non-cirrhotic HCV-4,-5 and -6 treatment-naive or treatment-resistant adults. The cure rates range from 97 - 100% in HCV-1.
    • SURVEYOR-II is assessing ABT-493 and ABT-530, with and without ribavirin, in cirrhotic and non-cirrhotic adults with HCV-2 or -3 who were new to therapy or had failed earlier treatment with interferon/ribavirin. The cure rates range from 96 - 100% in HCV-2 and 83 - 94% in HCV-3.
    • ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, are being developed for the pan-genotypic (genotypes 1-6) treatment of HCV infection. ABT-493 was discovered under the company's collaboration with Enanta Pharmaceuticals (ENTA -1.2%). A Phase 3 trial in genotypes 1-6 was initiated this month.
    • Related tickers: (MRK +0.4%)(GILD +0.1%)(BMY +0.2%)(JNJ +0.8%)
    | Nov. 16, 2015, 10:07 AM | 45 Comments
  • Nov. 16, 2015, 7:42 AM
    • Preliminary results from a Phase 2a clinical trial, OSIRIS, showed HCV-4 patients treated with Janssen's (NYSE:JNJ) OLYSIO (simeprevir) and Gilead Sciences' (NASDAQ:GILD) Sovaldi (sofosbuvir) for 12 weeks achieved cure rates as high as 100%. The data were presented at The Liver Meeting in San Francisco.
    • OSIRIS assessed the regimen of simeprevir 150 mg and sofosbuvir 400 mg in 63 HCV-4 patients, both treatment-naive and treatment-experienced, with and without cirrhosis. Patients without cirrhosis were randomized to receive either eight or 12 weeks of therapy while patients with cirrhosis received 12 weeks of treatment.
    • Results showed a 100% cure rate (SVR12) in patients treated for 12 weeks (n=43) and 75% (n=20) in patients treated for eight weeks. Five patients in the eight-week group relapsed, all were genotype IL28B non-CC and non-responders to other therapies.
    • HCV-4 is the most common type of HCV infection in the Middle East. As many as 10% of Egyptians are HCV-positive, almost all genotype 4.
    • Related tickers: (NYSE:ABBV) (NASDAQ:ENTA) (NYSE:MRK)
    | Nov. 16, 2015, 7:42 AM | 5 Comments